IRCCS Eugenio Medea   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Bosisio Parini Italy (1985)

Organization Overview

First Clinical Trial
2012
NCT01796262
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

IRCCS 'Eugenio Medea' | IRCCS Eugenio Medea | Maria Nobile

Active Ingredients

Drugs in Phase 4 Trials (1)

methylphenidate (ritalin) (1 trial)

Drugs in Phase 3 Trials (2)

omega-3 fatty acids (Omacor) (1 trial)

wheat (1 trial)

Drugs in Phase 2 Trials (2)

etravirine (intelence) (1 trial)

interferon gamma-1b (actimmune) (1 trial)

Drugs in Other Trials (2)

fiber (1 trial)

prebiotic fiber (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ataxia (Phase 2)

Attention Deficit Disorder with Hyperactivity (Phase 4)

Cerebellar Ataxia (Phase 2)

Friedreich Ataxia (Phase 2)

Hyperkinesis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 7